Ascent Group LLC Purchases 937 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Ascent Group LLC increased its holdings in Regeneron Pharmaceuticals by 242.1%, acquiring an additional 937 shares to own a total of 1,324 shares valued at $840,000.
• Research analysts have varying ratings for Regeneron Pharmaceuticals, with a consensus target price of $817.67 and a majority rating it as a Moderate Buy.
• The company declared a quarterly dividend of $0.88 per share, indicating an annualized yield of 0.6% and a payout ratio of 8.87%.

Ascent Group LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 242.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 1,324 shares of the biopharmaceutical company's stock after acquiring an additional 937 shares during the period. Ascent Group LLC's holdings in Regeneron Pharmaceuticals were worth $840,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Marietta Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after acquiring an additional 2,501 shares during the last quarter. Sepio Capital LP increased its position in shares of Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after buying an additional 842 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after buying an additional 814,713 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares in the last quarter. Finally, KBC Group NV increased its position in shares of Regeneron Pharmaceuticals by 9.4% in the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after buying an additional 12,793 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $8.20 during mid-day trading on Friday, reaching $560.00. The stock had a trading volume of 602,540 shares, compared to its average volume of 942,825. The stock has a 50-day simple moving average of $564.61 and a two-hundred day simple moving average of $579.66. The stock has a market capitalization of $59.35 billion, a PE ratio of 14.11, a P/E/G ratio of 1.90 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,170.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same period last year, the firm posted $11.56 earnings per share. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent analyst reports. Morgan Stanley restated an "overweight" rating and issued a $761.00 price objective (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Jefferies Financial Group increased their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research note on Wednesday, August 27th. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Finally, Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.